A Study of SKB518 in Patients With Lung Cancer

Summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

Timeline

Start

2025-08-29

Primary completion

2027-02-20

Completion

2027-10-20

Drugs

Indications